latest wording, from 10-K.....
The Company retained ownership of all its other
assets, including its core yeast technology for developing drug discovery
assays, its collection of over 25,000 proprietary yeast strains, human and
mammalian cell lines, and genetic engineering tools, its joint ownership of the
human orphan G Protein-coupled receptors identified pursuant to its
collaboration with Genomic Therapeutics Corporation, its proprietary software,
its genomics databases related to G Protein-coupled receptors, all assays and
technologies reverting to it from its collaboration with Bristol-Myers Squibb
Company, a 30% equity position in Axiom Biotechnologies Inc., the Company's cash
and cash equivalents, and the approximately $19.1 million being held in escrow
pending appeal of the verdict in favor of SIBIA. |
